Home › Trials › NCT06297226

CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Phase 2 Interventional Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06297226

This study is testing a new CAR T cell therapy to see if it can help adults with multiple myeloma who haven't had success with other treatments.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment230 (estimated)
Ages18 Years and up
SexAll
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company Industry-sponsored
Locations52 sites (Birmingham, Alabama and 51 other locations)
Trial IDNCT06297226 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393), a CAR T cell therapy targeting GPRC5D, in adults with relapsed or refractory multiple myeloma. Participants must have a documented diagnosis of multiple myeloma and have undergone at least three prior lines of therapy. The study aims to assess how well this innovative treatment can manage the disease in patients who have not responded to previous treatments.

Who should consider this trial

Good fit: Ideal candidates are adults with relapsed or refractory multiple myeloma who have received multiple lines of prior therapy.

Not a fit: Patients with active central nervous system involvement or those who have received prior therapies targeting GPRC5D may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could provide a new treatment option for patients with difficult-to-treat multiple myeloma.

How similar studies have performed: Other studies using CAR T cell therapies have shown promising results in treating multiple myeloma, indicating potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
* Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT).
* Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
* Participants must have measurable disease during screening.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria

* Active or history of central nervous system involvement with MM.
* Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded.
* Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Birmingham, Alabama and 51 other locations

+2 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaRelapsed or Refractory Multiple MyelomaBMS-986393CAR T Cell TherapyRRMMArlocabtagene Autoleucel
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.